COMPANY UPDATES
16
Dec
2019
Novoheart Licenses Harvard Technology to Develop Next-Generation Human Heart-in-a-Jar

Novoheart announced an exclusive licensing agreement with Harvard University's Office of Technology Development and to develop the next-generation human heart-in-a-jar.

30
Nov
2019
Novoheart Announces Change of Fiscal Year-End and Grants Stock Options

Novoheart announced that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30. Also, the Company has granted incentive stock options to purchase common shares of the Company to directors and employees of the Company.

30
Nov
2019
Novoheart Provides Corporate Update

Novoheart announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Camie Chan, Chief Operating Officer, will simultaneously serve as the Interim Chief Financial Officer and Corporate Secretary during the transition.

26
Nov
2019
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca

Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!